Wednesday, December 07, 2016 11:14:41 AM
NEXT ON THE SEC AGENDA FAKE NEWS ??
This would not be a big stretch in light of yesterdays SCOTUS decision on insider trading. A direct compensation link is no longer needed to prosecute, thus reversing the Appellate 2nd Circuit decision last year.
SEC has already gone after fake news to aid a trading position
https://www.sec.gov/news/press/2008/2008-64.htm
Fake news / rumors whatever one calls it - if a linkage can be found the SEC would appear to have grounds.
On a TA note the acceleration of the downtrend that started on 11/14 is conforming that rate of decent. If maintained it would predict a maximum price of 90 cents as of 12/31/16. Minimum price on that date 75 cents.
trendliner
This would not be a big stretch in light of yesterdays SCOTUS decision on insider trading. A direct compensation link is no longer needed to prosecute, thus reversing the Appellate 2nd Circuit decision last year.
SEC has already gone after fake news to aid a trading position
https://www.sec.gov/news/press/2008/2008-64.htm
Fake news / rumors whatever one calls it - if a linkage can be found the SEC would appear to have grounds.
On a TA note the acceleration of the downtrend that started on 11/14 is conforming that rate of decent. If maintained it would predict a maximum price of 90 cents as of 12/31/16. Minimum price on that date 75 cents.
trendliner
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
